Organogenesis of the kidney glomerulus: Focus on the glomerular basement membrane

Jeffrey H. Miner
Washington University School of Medicine in St. Louis

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
http://digitalcommons.wustl.edu/open_access_pubs/2536
Organogenesis of the kidney glomerulus
Focus on the glomerular basement membrane

Jeffrey H. Miner
Renal Division; Department of Internal Medicine; Washington University School of Medicine; St. Louis, MO USA

The glomerular basement membrane (GBM) is a crucial component of the kidney’s filtration barrier that separates the vasculature from the urinary space. During glomerulogenesis, the GBM is formed from fusion of two distinct basement membranes, one synthesized by the glomerular epithelial cell (podocyte) and the other by the glomerular endothelial cell. The main components of the GBM are laminin-521 (α5β2γ1), collagen α3α4α5(IV), nidogen and the heparan sulfate proteoglycan, agrin. By studying mice lacking specific GBM components, we have shown that during glomerulogenesis, laminin is the only one that is required for GBM integrity and in turn, the GBM is required for completion of glomerulogenesis and glomerular vascularization. In addition, our results from laminin β2-null mice suggest that laminin-521, and thus the GBM, contribute to the establishment and maintenance of the glomerular filtration barrier to plasma albumin. In contrast, mutations that affect GBM collagen IV or agrin do not impair glomerular development or cause immediate leakage of plasma proteins. However, collagen IV mutation, which causes Alport syndrome and ESRD in humans, leads to gradual damage to the GBM that eventually leads to albuminuria and renal failure. These results highlight the importance of the GBM for establishing and maintaining a perfectly functioning, highly selective glomerular filter.

Introduction

Human kidneys generate an enormous primary filtrate of about 180 liters from the approximately 900 L of blood that pass through them on a daily basis. Due to resorption of water and solutes by the tubular epithelial cells of the kidney, this primary filtrate is concentrated to a urinary output of only 1–2 L. The glomerular filtration barrier, which lies between the vasculature and the urinary space, retards the passage of plasma proteins, primarily of albumin and immunoglobulins, while ensuring the efficient flow of water and small solutes that comprise the primary filtrate. Since the realization that the glomerular capillary wall consists of two cells, podocyte and endothelium, separated by an extracellular matrix called the glomerular basement membrane (GBM), there have been vigorous debates about which of these three layers serves as the major barrier to plasma proteins. In this review, I will summarize our current understanding of the cellular and extracellular components of the glomerular capillary wall and focus on the composition of the GBM as it relates to glomerulogenesis, permselectivity and kidney disease.
Podocytes, also called glomerular visceral epithelial cells, are morphologically complex, nascent nephron epithelium-derived cells that reside within the urinary space (also called Bowman’s space) and are therefore bathed in the primary urine. Podocytes enwrap the outer aspect of the glomerular capillaries by extending narrow foot processes that interdigitate with those of adjacent podocytes. Juxtaposed foot processes are directly linked to one another by the glomerular slit diaphragms (Fig. 1); these derive from gradual modification and apical-to-basal migration of the tight junctions that originally joined the previously columnar, immature podocytes.

Like the tubular epithelial cells of the nephron, podocytes are descendants of the metanephric mesenchyme, a population of intermediate mesoderm-derived cells that are determined to form nephrons. At the beginning of development of the definitive kidney, the ureteric bud grows towards and into the metanephric mesenchyme and induces it to condense and undergo a dramatic mesenchyme-to-epithelium transition to form what is referred to as the renal vesicle. Activation of numerous important signaling pathways results in morphological changes to the renal vesicle and segmentation of the resulting “S-shaped” figure into the podocytes, the parietal epithelial cells that form Bowman’s capsule, and the epithelial cells that comprise the tubular segments of the nephron.

Glomerular Endothelial Cells

Glomerular capillaries are lined by endothelial cells that are different than most, because they bear many fenestrations (Fig. 1). Fenestrations are seemingly patent “holes” in the endothelial cells that allow the passage of fluid across the cell layer. Ultrastructural analyses have shown that some of these fenestrations have wagon wheel-like diaphragms similar to those found in peritubular capillaries and in islet endothelial cells in the pancreas, but many of the fenestrations in glomerular endothelial cells do not have diaphragms. This lack of diaphragms likely allows more efficient flow of plasma across this proximal layer of the glomerular filtration barrier.

Despite the presence of what usually appear by electron microscopy to be unobstructed fenestrae in the glomerular endothelium, special methods of fixation and staining indicate the presence of filamentous plugs in the fenestrations. These plugs are thought to be composed of a form of glycocalyx (a sugary coat) assembled by the glomerular endothelial cells at their cell surfaces. These fenestral plugs have been hypothesized to serve as an impedance to the passage of plasma proteins and therefore an important component of the glomerular filtration barrier to albumin.

### Glomerular Basement Membrane (GBM)

The GBM is, in some ways, a typical basement membrane: it has an electron-dense lamina densa when viewed by transmission electron microscopy, and it is formed by protein-protein interactions among the same classes of macromolecules found in all other basement membranes. However, the GBM also has some atypical features. First, it is unusually thick compared to most other basement membranes; as mentioned above, the GBM forms during glomerulogenesis by the fusion of two distinct basement membranes, the endothelial and the visceral epithelial (or podocyte) basement membranes. Second, the GBM has an unusual composition compared to most other basement membranes, and this presumably imparts its unique functional properties. The GBM contains laminin, type IV collagen, nidogen and heparan sulfate proteoglycan (HSPG), components found in all basement membranes, but for some of these types of matrix proteins, the specific isoforms present in the GBM are very different than those found elsewhere in basement membranes. Even the contiguous Bowman’s capsule and tubular basement membranes, for example, possess different complements of isoforms compared to the GBM.

The GBM occupies a prime position within the glomerular filtration barrier (Fig. 1). In addition, it is very dense by electron microscopy. Together with structural and functional data regarding the GBM and other basement membranes, published by many different labs over a period of decades, we hypothesize that the GBM functions by (1) providing adhesive and signaling substrates to the adjacent glomerular cells (podocytes, endothelial...
cells and mesangial cells); (2) concentrating and presenting diffusible factors, such as vascular endothelial growth factor; and (3) contributing directly to the glomerular filtration barrier to albumin. These functions, if correct, likely depend upon the composition of the GBM, which will now be discussed.

**Laminin**

Laminins are a family of large, evolutionarily related glycosylated proteins that assemble with each other to form at least 15 different αβγ heterotrimeric macromolecules. These laminin trimers are synthesized and secreted by diverse cell types into the extracellular space. Laminin trimers in the most recent laminin nomenclature scheme are named based solely on their chain composition; e.g., a trimer containing the laminin α5, β2 and γ1 chains is called laminin-521, or LM-521. Most laminin heterotrimers are cross-shaped macromolecules (LM-521 is shown in Fig. 2), with the one “long arm” formed by association of the α, β and γ chains via coiled-coil interactions and disulfide bonding. The three free “short arms” contain NH₂-terminal globular domains (called LN domains) that mediate laminin trimer-trimer interactions in the extracellular space. These interactions lead to laminin polymerization, which initiates basement membrane formation. The ~100 kDa laminin globular (LG) domain at the distal end of the long arm (found exclusively at the COOH termini of α chains) mediates interactions with integrin and nonintegrin receptors on the surfaces of cells. A number of studies have shown that laminin polymerization in the extracellular space is required for initiation of basement membrane formation. Moreover, laminin polymerization via short arm-short arm interactions is facilitated by LG domain interactions with cellular receptors, likely due in part to the increase in effective laminin concentration that results at cell surfaces. Intracellular signaling events induced by laminin binding are also involved in promoting laminin polymerization and basement membrane formation.12

LM-521 is the major laminin found in the mature GBM, and it is secreted by both podocytes and endothelial cells.2 During the early stages of glomerulogenesis, when glomerular endothelial cells are migrating towards the differentiating podocytes to begin to form the glomerular capillaries, and the GBM is first recognizable as a distinct basement membrane, LM-111 and LM-511 are the major laminin components.13 But as capillary maturation begins, LM-521 is deposited by both podocytes and endothelial cells, and LM-111 and -511 are eventually eliminated.13,14 The molecular mechanisms that drive the developmental transitions in laminin expression and deposition have yet to be discovered, but as discussed below, these transitions are crucial to ensure the establishment of a proper glomerular filtration barrier.

**Type IV Collagen**

Type IV collagen, like all collagens, is secreted as a trimer (also called protomer) composed of three α chains, the sequences of which include collagenous regions that consist of repeated Gly-X-Y amino acid triplets. The presence of glycine at every third residue is absolutely necessary to allow the chains to assemble into a stable triple helix; this is because glycine is the only amino acid with a side chain (a hydrogen) that is able to fit at the center of the helix. But unlike the rigid fibril-forming types of collagen that are associated with bone and tendon, for example, the six distinct collagen IV α chains contain numerous interruptions of the Gly-X-Y repeats that are scattered throughout the collagenous domain. These interruptions provide flexibility to the collagen IV trimers and therefore to the collagen IV network, which is formed by covalent and noncovalent interactions among trimers in the extracellular matrix.15

Besides the central collagenous region containing the Gly-X-Y interruptions, all six collagen IV α chains bear a small noncollagenous NH₂-terminal domain called 7S and a larger COOH-terminal noncollagenous domain called NC1. Both of these domains are crucial for linking trimers to each other to promote collagen IV network formation. Moreover, the NC1 domain plays an important role in directing the composition of collagen IV heterotrimers; information present within the NC1 domain sequence ensures that only three types of collagen IV trimers form: (α1)₃, (α2)₃, (α3)₃ and (α5)₂(α6).16

---

**Figure 2.** The laminin-521 heterotrimer. This full-sized cruciform laminin is composed of the α5, β2 and γ1 chains. Globular laminin amino-terminal (LN) domains interact with each other to facilitate laminin polymerization in the extracellular matrix. The α chain laminin globular (LG) domain is recognized by receptors on cells, such as integrins, dystroglycan and the Lutheran blood group glycoprotein.
The collagen IV network of the mature GBM consists primarily of α3/α4/α5 heterotrimers. Grafting experiments in vivo have shown that podocytes but not endothelial cells synthesize the α3/α4/α5 network, so it is likely the small amount of collagen α1 and α2(IV) chains that are present in the mature GBM derive mainly from glomerular endothelial cells. Similar to the situation for laminins discussed above, there are developmental transitions in collagen IV gene expression and collagen trimer deposition during glomerulogenesis. At the earliest stages, only the α1 and α2(IV) chains are detected, but as the glomerular capillaries begin to mature, there is a gradual increase in deposition of the α3, α4 and α5 chains. This developmental transition in collagen IV network production has been shown to occur during human, dog and mouse kidney development.

**Nidogens**

There are two nidogen proteins. Each is a dumbbell-shaped basement membrane component that binds tightly to the laminin γ1 chain short arm as well as to type IV collagen. Therefore, nidogen was thought initially to be crucial for basement membrane formation as a potential link between the separate laminin and type IV collagen networks. However, analysis of single and double nidogen-1 and -2 knockout mice proved that basement membranes can form in the absence of either or both nidogen proteins, although some basement membranes subjected to high levels of stress during embryogenesis exhibit breaks and discontinuities in the absence of both nidogens. As far as the GBM is concerned, both nidogens-1 and -2 are present, but little is known about their differential expression during development.

**Heparan Sulfate Proteoglycans (HSPGs)**

HSPGs consist of a protein core with covalently linked glycosaminoglycan side chains that can dramatically increase the molecular weight of the molecule. The side chains are frequently modified by sulfation, which confers a significant anionic charge to the proteoglycan and thus to the basement membrane (or other extracellular matrix) in which the proteoglycan is located. Although perlecan is probably the most common HSPG found in most basement membranes, the mature GBM contains very little perlecan but, instead, contains primarily agrin. Agrin plays an important role in the neuromuscular system, where a special isoform secreted by motor neurons is crucial for development and organization of the neuromuscular junction. Although agrin is the major GBM HSPG at maturity, during glomerular development there appears to be a codistribution of agrin and perlecan, and then perlecan disappears from the GBM and becomes confined to the mesangial matrix.

**The GBM’s Contribution to Glomerulogenesis**

Evidence that the GBM plays an important role in glomerulogenesis comes from our studies of laminin α5 mutant and transgenic mice. As alluded to above, during glomerulogenesis there are developmental transitions in GBM components, including transitions from LM-111 to LM-511 and then to LM-521, which is the mature isoform. The appearance of LM-511 in the nascent GBM is accompanied by the abrupt removal/disappearance of LM-111 by an unknown mechanism. When laminin α5 is knocked out, LM-111 is still removed, and because there is no polymerizing laminin trimer present, the integrity of the GBM is compromised, and it breaks down. Without a GBM, none of the three glomerular cell types are able to maintain their positions within the developing glomerulus, leading to a disorganized glomerulus and failed glomerular vasculization. Subsequent studies of specific segments of the laminin α5 COOH-terminal LG domain reveal a previously unknown role for laminin α5 in mediating adhesion of mesangial cells to the GBM; this adhesion is required for maintaining the capillary tubing that is a major anatomical characteristic of the glomerular tuft.

**The GBM’s Contribution to Perme selectivity**

Since the discovery that nephrin (NPHS1), a primary component of the glomerular slit diaphragm, is mutated in congenital nephrotic syndrome of the Finnish type, podocytes have been the major focus of research aimed at defining the nature of the glomerular filtration barrier and understanding the etiology of glomerular disease. There is now known to be a

---

**Figure 3.** Schematic diagram showing that GBM breakdown due to Lama5 mutation results in failed glomerulogenesis. (A) A maturing wild-type (Lama5+/+) glomerulus with an intact podocyte epithelium (green) and endothelium (yellow) flanking the GBM (red). Mesangial cells (blue) are centrally located within the GBM, and parietal epithelial cells (not shown) sit on the Bowman’s capsule basement membrane (orange) and line Bowman’s space. (B) Failed glomerulogenesis in a Lama5−/− kidney. Discontinuities in the GBM (red) lead to stratification of the podocyte layer (green) and disorganized endothelial and mesangial cells (yellow and blue, respectively).
large cohort of genes expressed in podocytes, the mutation of which in humans and/or mice causes defects in glomerular permselectivity, nephrotic range proteinuria and in some cases, focal segmental glomerulosclerosis. This certainly lends support to the concept that podocytes are crucial for establishing and maintaining the glomerular filtration barrier. However, the GBM should not be ignored or forgotten. Of the nine proteins that are known to be present in the mature GBM, mutations that affect four of them cause glomerular disease in humans (as well as in mice), and mutation of a fifth causes nephrotic syndrome in mice. These will now be discussed.

The first GBM protein shown to be affected in a human disease is collagen α5(IV), which is encoded by COL4A5. Mutations in COL4A5 cause the X-linked form of Alport syndrome, a hereditary glomerulonephritis leading to kidney failure. As discussed above, the α5 chain is a component of the α3α4α5(IV) trimer that is present in the mature GBM. In the absence of α5(IV), these trimers, and thus the network they would normally form within the GBM, are totally absent. Likewise, homozygous or compound heterozygous mutations that affect the autosomal COL4A3 or COL4A4 genes also prevent production of the α3α4α5(IV) trimer and cause the more rare, autosomal recessive form of Alport syndrome.

In the absence of the usual collagen α3α4α5(IV) network that is present in the GBM, there is substitution or compensation by the (α1)α2(IV) network. Interestingly, in some Col4a3-/- Alport mice, especially those on the C57BL/6J strain background, there is also compensation in the GBM by the (α5)α6(IV) network, which may slow progression of the disease. Although this network functions adequately for several years in most Alport syndrome patients, eventually there is a characteristic splitting and thickening of the GBM, visible by electron microscopy (Fig. 4), that sometimes imparts a “basket weave” appearance. This pathology is associated first with hematuria and later with proteinuria. Because proteinuria is a relatively late feature of Alport syndrome, it seems that the identity of the collagen IV network is not an important determinant of glomerular permselectivity. It is important to note here that dominant mutations in human COL4A1, which encodes the collagen α1(IV) chain, also cause several forms of kidney disease, and there are a number of interesting extrarenal manifestations.

In contrast to the delayed onset proteinuria that develops in patients with Alport syndrome, those with Pierson syndrome, which is caused by truncating or severe missense mutations in the laminin β2 gene LAMB2, exhibit congenital nephrotic syndrome and diffuse mesangial sclerosis together with extrarenal manifestation such as small pupils (microcoria) and neurological abnormalities. Lamb2-/- mice exhibit a phenotype that is consistent with that observed in Pierson syndrome patients, including nephrotic syndrome, severe neuromuscular abnormalities and retinal defects. Interestingly, unlike the GBM breakdown that occurs in mice lacking laminin α5, GBM integrity is maintained in the absence of laminin β2. This is likely because there is retention of laminin β1 in the mature Lamb2-/- GBM as part of LM-511 and ectopically deposited LM-111, LM-211 and perhaps LM-311. We concluded initially that laminin β1 compensates structurally for the missing laminin β2 but cannot compensate functionally. However, currently we are testing the alternative hypothesis that the remaining laminin β1 in the GBM is quantitatively insufficient compared to the level of laminin β2 that is normally present, and that artificially increasing the level of β1 will increase the concentration of laminin trimers in the GBM and thereby greatly improve the filtration barrier, perhaps by increasing the density of the GBM.

Patients with what seem to be “less severe” missense LAMB2 mutations also have nephrotic syndrome, but it is accompanied by significantly milder extrarenal defects. These data suggest that laminin β2 and the laminin-521 trimer of which it is a component contribute to the glomerular filter by imparting appropriate barrier properties to the GBM. Indeed, our studies of Lamb2-/- mice showed clearly that albuminuria is detectable before foot process effacement and loss of slit diaphragms. Furthermore, foot process and slit diaphragm formation normally occurs in the absence of LM-521. The straightforward interpretation is that albumin leaks across the filtration barrier because the GBM is defective, indicating that the GBM must normally serve as an important component of the filtration barrier. Loss of foot processes is likely a secondary response to proteinuria, but this remains to be investigated.

We recently investigated the mechanism whereby a particular pathogenic LAMB2 missense mutation (R246Q)
found in a Turkish family\textsuperscript{42} causes congenital nephrotic syndrome. The mutation was engineered into the rat laminin $\beta_2$ cDNA and expressed in the podocytes of transgenic mice in vivo via the mouse nephrin promoter.\textsuperscript{44} Transgenes from three different founder lines were expressed at different relative levels, determined to be high, medium and low based on mutant protein accumulation in the GBM. These three transgenes were bred individually onto the $\text{Lamb}_2^{-/-}$ background, so that all laminin $\beta_2$ in the GBM derived from the mutant transgene. These mice developed proteinuria, the level of which was inversely proportional to the level of laminin $\beta_2$ mRNA in podocytes that were higher than that normally observed for endogenous mouse laminin $\beta_2$, suggesting that the nephrin promoter was more than adequate for driving the production of mutant laminin $\beta_2$ mRNA, in agreement with our previous studies\textsuperscript{41} and\textsuperscript{45}. Because studies of the R246Q mutant in transfected 293 cells suggest that the mutation somehow inhibits laminin secretion, we concluded that this mutation causes misfolding and degradation of most of the laminin $\beta_2$ polypeptide, but that the increased transcription imparted by the nephrin promoter allows the podocytes to overcome the secretion defect and secrete enough LM-521 into the GBM to make a partly functional albumin barrier.\textsuperscript{44}

Concerning the other components of the GBM, lack of either nidogen-1 or nidogen-2 results in viable mice\textsuperscript{20} and no significant defects in glomerular filtration. Similarly, podocyte-specific knockout of agrin, which leads to its absence from the GBM, has no discernible effect on the filtration barrier, although its loss causes a dramatic reduction in the GBM's concentration of negatively charged sites.\textsuperscript{43} Finally, although no mutations affecting human laminin $\alpha_5$ or laminin $\gamma_1$ have been discovered, likely due to early prenatal lethality that should occur due to widespread expression of both chains during embryogenesis, podocyte-specific mutation of $\text{Lama}_5$ in mice results in proteinuria that, in many cases, progresses to nephrotic syndrome and renal failure.\textsuperscript{29}

Questions and Answers

Dr. Dwight Towler, Ira M. Lang Professor of Medicine and Developmental Biology, Washington University School of Medicine: I am curious about the potential for acquired dysfunctions in the laminin $\beta$ chains. On that particular Arg246 of laminin $\beta_2$, is it susceptible to modification by advanced glycation end products, for example? Do you know whether or not one or more N-carboxymethyl arginine derivatives, advanced glycosylation end products described in collagen in the setting of diabetes, could also modify and nullify the function of that $\beta$ chain?

Dr. Jeffrey Miner: I don’t think anyone has looked at specific residues of laminins in the setting of hyperglycemia.

Dr. Towler: The structure-function implications from the family with Pierson syndrome phenotypes and your elegant data point to that possibility. It is clearly an important region of laminin $\beta_2$ with respect to glomerular basement membrane function and proteinuria; I was wondering whether or not some of the acquired albu-minuria states and GBM deficiencies also relate to biochemical modifications of that same $\beta_2$ arginine residue.

Dr. Miner: No, not that I know of.

Dr. Towler: I know this presentation was “focused on the filter,” but I was curious about your hypomorphic mutation of the $\alpha_5$ chain C terminus. Did you happen to note any structural defects that occurred in the peritubular basement membranes, where laminin-511 might be important?

Dr. Miner: We did not, we focused on the filter. That was the only place where we found any obvious abnormalities. The tubular basement membranes also have other laminins. It is not pure LM-511.

Dr. Towler: So do you think that the mesangial cell interaction with the COOH terminus of laminin $\alpha_5$ is a fairly specific interaction in the glomerular basement membrane?

Dr. Miner: Yes

Dr. Feng Chen, Assistant Professor of Medicine and Cell Biology and Physiology, Washington University School of Medicine: Have you looked to see if you have phenotypes in animals that are...
heterozygous for the β1 chain, the β2 chain or trans-heterozygous for β1 and β2? Your hypothesis predicts that it is a quantitative rather than a qualitative deficiency.

Dr. Miner: In every laminin mutant that I know of there has never been a defect shown in a heterozygote. Even though it is quantitatively less transcription, the proteins are so long lived that it doesn’t seem to take much mRNA to make a normal basement membrane protein complement.

Dr. Kopan: What if you reduce the β1 on the β2 knockout background?

Dr. Miner: We haven’t done that. We have β1 knockout animals; we should do that experiment.

Dr. Helen Liapis, Professor of Pathology and Immunology, Washington University School of Medicine: You mentioned podocyte foot process effacement as being caused by a variety of conditions, and your last diagram also points out that defects in a lot of molecules may lead to the same result. However, there are nephrotic syndromes that are not associated with foot process effacement. Can you try to explain that?

Dr. Miner: Well I know of endothelial cell injury in preeclampsia, and you try to explain that?

Dr. Miner: You mean in mice? No. In theory, it should work in humans as well, but no one has ever seen that same ectopic α5/5/6 collagen IV network in human Alport patients. It seems to be a mouse-specific phenomenon and has only been shown to occur on the C57BL/6J background. The senior author of that paper thinks that there is actually a SNP, or a difference in the promoter of α5/6, that allows high levels of α6 to be made. And of course, most human Alport patients have α5 mutations, so even if you could activate α6 expression in podocytes, it would not help without the α5. So that approach couldn’t work for most patients.

Acknowledgements

My relevant research is supported by NIH grants R01DK078314, R01GM060432 and R01DK081156.

Note

Edited transcripts of research conferences sponsored by Organogenesis and the Washington University George M. O’Brien Center for Kidney Disease Research (P30 DK079333) are published in Organogenesis. These conferences cover organogenesis in all multicellular organisms, including research into tissue engineering, artificial organs and organ substitutes and are participated in by faculty at Washington University School of Medicine, St. Louis, MO USA.

References


